Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer

Cancer Biomarkers

Volumn 13, Issue 2, 2013, Pages 89-97

  Wang, Jianfei ^a   Yang, Hongying ^a   Shen, Yinchen ^a   Wang, Shuai ^a   Lin, Dongmei ^a   Ma, Li ^a   Han, Xiaohong ^a   Shi, Yuankai ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Colorectal cancer; direct sequencing; KRAS; mutation detection

Indexed keywords

K RAS PROTEIN;

ADULT; AGED; ARTICLE; ASSAY; CANCER PATIENT; CHINESE; CLINICAL FEATURE; CODON; COLORECTAL CANCER; DIRECT SEQUENCING; FEMALE; GENE MUTATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGED; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SEQUENCE ANALYSIS, DNA;

EID: 84880531371     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-130334     Document Type: Article

References (28)

1. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345. (Pubitemid 38944402)
2. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
3. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
4. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
5. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
6. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitu-mumab with infusional fluorouracil, leucovorin, and oxali-platin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorec-tal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705.
7. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-2096.
8. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
9. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetux-imab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572.
10. De Roock W, Claes B, Bernasconi D, De Schutter J, Bies-mans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorec-tal cancer: A retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
11. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308. (Pubitemid 46480970)
12. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643-2648. (Pubitemid 46548951)
13. Wang Z, Wu YL, Zhang GC, Zhou Q, Xu CR, Guo AL. EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients. Onkologie 2008; 31: 174-178. (Pubitemid 351700540)
14. Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans TJ, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 2009; 11: 543-552.
15. Franklin WA, Haney J, Sugita M, Bemis L, Jimeno A, Messersmith WA. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 2010; 12: 43-50.
16. Zhang H, Zheng X, Ji T, Fu L, Bai D, Liao Y, et al. Comparative screening of K-ras mutations in colorectal cancer and lung cancer patients using a novel real-time PCR with ADx-K-ras kit and Sanger DNA sequencing. Cell Biochem Biophys 2012; 62: 415-420.
17. Fakih MM. KRAS mutation screening in colorectal cancer: From paper to practice. Clin Colorectal Cancer 2010; 9: 22-30.
18. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009; 4: e7287.
19. Chang YS, Yeh KT, Chang TJ, Chai C, Lu HC, Hsu NC, et al. Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer 2009; 9: 179.
20. Liao W, Liao Y, Zhou JX, Xie J, Chen J, Huang W, et al. Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers. Anat Rec (Hoboken) 2010; 293: 1506-1511.
21. Shen H, Yuan Y, Hu HG, Zhong X, Ye XX, Li MD, et al. Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. World J Gastroenterol 2011; 17: 809-816.
22. Liou JM, Wu MS, Shun CT, Chiu HM, Chen MJ, Chen CC, et al. Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. Int J Colorectal Dis 2011; 6: 1387-1395.
23. Li HT, Lu YY, An YX, Wang X, Zhao QC. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol Rep 2011; 25: 1691-1697.
24. Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, Liu TC. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. Clin Chim Acta 2012, [Epub ahead of print].
25. Mao C, Zhou J, Yang Z, Huang Y, Wu X, Shen H, et al. KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer. PLoS One 2012; 7: e36653.
26. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 2009; 205: 858-862.
27. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69: 1851-1857.
28. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-721. Chinese Academy of Medical Sciences